Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Owlet, Inc.OWLT · Entity 6551 | Director | October 16, 2025 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Owlet, Inc.
Report date October 16, 2025 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,787 |
Ending reported balance
After 2026-08-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-10-16 · Grant · Acquired 18,996 · Balance 108,002 F1: This transaction is being reported late due to an administrative oversight. F2: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of the Company's common stock for each RSU upon vesting. The RSUs will fully vest on the earlier of (a) the first anniversary of the date of grant or (b) immediately prior to the next annual meeting of the Company's stockholders after the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. Row 2 · 2026-08-12 · Grant · Acquired 26,785 · Balance 134,787 F1: This transaction is being reported late due to an administrative oversight. F2: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of the Company's common stock for each RSU upon vesting. The RSUs will fully vest on the earlier of (a) the first anniversary of the date of grant or (b) immediately prior to the next annual meeting of the Company's stockholders after the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction is being reported late due to an administrative oversight.
F2: Constitutes restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of the Company's common stock for each RSU upon vesting. The RSUs will fully vest on the earlier of (a) the first anniversary of the date of grant or (b) immediately prior to the next annual meeting of the Company's stockholders after the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CERNER Corp
Report date November 02, 2018 · Filed November 05, 2018
Section 16 reporting ended · disclosed 2018-11-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby 401(k) Plan | 13,290 |
Reported balance
Holding disclosure · report date 2018-11-02 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 13,290 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.91 · Expires 2025-03-12 | Direct | 73,000 |
Reported balance
Holding disclosure · report date 2018-11-02 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 73,000 |
Livongo Health, Inc.
Report date October 30, 2020 · Filed October 30, 2020
Section 16 reporting ended · disclosed 2020-10-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 911,730 |
Reported balance
After 2020-10-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-10-30 · Disposition to issuer · Disposed 5,000 · Balance 911,730 F1: Represents restricted stock units ("RSUs") voluntarily forfeited to the Issuer. F2: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-10-30 · Disposition to issuer · Disposed 911,730 · Balance 0 F3: Includes 72,652 RSUs and 491,149 shares of restricted stock. F4: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F5: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F6: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. F7: Pursuant to the Merger Agreement, each outstanding award of restricted stock of the Issuer was converted into an award of a number of shares of restricted Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such restricted stock award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer restrict stock award immediately prior to the effective time of the merger (including applicable vesting conditions). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") voluntarily forfeited to the Issuer.
F2: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020.
F3: Includes 72,652 RSUs and 491,149 shares of restricted stock.
F4: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).
F5: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions).
F6: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.
F7: Pursuant to the Merger Agreement, each outstanding award of restricted stock of the Issuer was converted into an award of a number of shares of restricted Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such restricted stock award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer restrict stock award immediately prior to the effective time of the merger (including applicable vesting conditions).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 05, 2017 Filed Sep 6, 2017 16:45 UTC | CERNER Corp CERN · Entity 126375 | OtherCommon Stock | 20,000 | $38.43 | $768,600.00 |
DisclosureSEC source: 0001209191-17-051657 · doc4.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,799 F1 · balance_after: Includes 18,000 shares of restricted common stock. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 16:45 UTC | CERNER Corp CERN · Entity 126375 | GrantRestricted Stock Units · Derivative | 70,400 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-051657 · doc4.xml · derivative · entry 9 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,400 Underlying: Common Stock · 70,400 shares Expires 2019-09-01 F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Cerner Corporation common stock. The restricted stock units are eligible for vesting on 09/01/2019. F4 · shares: Each restricted stock unit represents a contingent right to receive one share of Cerner Corporation common stock. The restricted stock units are eligible for vesting on 09/01/2019. F5 · price: This transaction represents a grant of restricted stock units to the reporting person by the issuer. Therefore, no consideration other than the value of services rendered was paid for the security. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:28 UTC | CERNER Corp CERN · Entity 126375 | Tax withholdingCommon Stock | 5,840 | $66.70 | $389,528.00 |
DisclosureSEC source: 0001209191-17-037254 · doc4.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,799 F1 · shares: Shares of common stock withheld to satisfy the tax withholdings for the vesting of 14,400 shares of restricted common stock. F2 · balance_after: Includes 18,000 shares of restricted common stock. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 17:09 UTC | CERNER Corp CERN · Entity 126375 | GrantRestricted Stock Units · Derivative | 2,100 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-018837 · doc4.xml · derivative · entry 4 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 2,100 shares Expires 2018-03-05 F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Cerner Corporation common stock. The restricted stock units are eligible for vesting on 03/05/2018. F5 · shares: Each restricted stock unit represents a contingent right to receive one share of Cerner Corporation common stock. The restricted stock units are eligible for vesting on 03/05/2018. F6 · price: This transaction represents a grant of restricted stock units to the reporting person by the issuer. Therefore, no consideration other than the value of services rendered was paid for the security. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 17:09 UTC | CERNER Corp CERN · Entity 126375 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $55.74 | $0.00 |
DisclosureSEC source: 0001209191-17-018837 · doc4.xml · derivative · entry 3 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2027-03-03 F4 · price: This transaction represents a grant of options to the reporting person by the issuer. Therefore, no consideration other than the value of services rendered was paid for the security. F3 · derivative.exercise_date: Options are exercisable per the following schedule: 40% - 03/03/2019, 20% - 03/03/2020, 20% - 03/03/2021, 20% - 03/03/2022. Read SEC document |
| December 31, 2016 Filed Jan 13, 2017 16:38 UTC | CERNER Corp CERN · Entity 126375 | OtherCommon Stock | 161 | $54.20 | $8,726.20 |
DisclosureSEC source: 0001209191-17-003682 · doc5.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by 401(k) Plan Disclosed balance after: 13,135 F1 · kind: Represents shares acquired through routine payroll deduction and participation in the issuer's 401(k) plan between 01/03/2016 and 12/31/2016, at prices ranging from $50.88 to $57.41 per share. Balance is based on plan statement as of 12/31/2016. This transaction qualifies as a nondiscretionary transaction from a tax-qualified plan. F1 · price: Represents shares acquired through routine payroll deduction and participation in the issuer's 401(k) plan between 01/03/2016 and 12/31/2016, at prices ranging from $50.88 to $57.41 per share. Balance is based on plan statement as of 12/31/2016. This transaction qualifies as a nondiscretionary transaction from a tax-qualified plan. F2 · price: Full information regarding the number of shares purchased at each separate price will be provided upon request by the Commission staff, Cerner Corporation, or a Cerner shareholder. Read SEC document |
| September 06, 2016 Filed Sep 7, 2016 17:54 UTC | CERNER Corp CERN · Entity 126375 | Tax withholdingCommon Stock | 11,987 | $64.96 | $778,675.52 |
DisclosureSEC source: 0001209191-16-140452 · doc4.xml · nonDerivative · entry 1 BURKE ZANE M · CIK 0001213555 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,771 F1 · shares: Shares of common stock withheld to satisfy the tax withholdings for the vesting of 25,000 shares of restricted common stock. F2 · balance_after: Includes 32,400 shares of restricted common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.